Masitinib, Given Early in ALS Course, Extends Life, Trial Data Show

Masitinib, Given Early in ALS Course, Extends Life, Trial Data Show

299952

Masitinib, Given Early in ALS Course, Extends Life, Trial Data Show

Treatment with the investigational oral therapy masitinib can extend lifespan when given early in the course of amyotrophic lateral sclerosis (ALS), according to a new study. “These long-term survival data, with an average follow-up of 75 months since diagnosis, suggest that masitinib can offer a substantial survival benefit when treatment is initiated before severe loss of functionality,” Albert Ludolph, chairman of the department of neurology at University Hospital and Medical Faculty of Ulm and a…

You must be logged in to read/download the full post.